We are live on
!
Find out more
RG
Redmile Group Portfolio holdings
AUM
$1.51B
1-Year Est. Return
164.17%
This Fund
S&P 500
This Quarter
Est. Return
-3.36%
1 Year Est. Return
+164.17%
3 Year Est. Return
+929.47%
5 Year Est. Return
+823.75%
10 Year Est. Return
+18,826.17%
AUM
$5.73B
AUM Growth
-$1.02B
(-15%)
Cap. Flow
-$157M
Cap. Flow
% of AUM
-2.73%
Top 10 Holdings %
Top 10 Hldgs %
44.42%
Holding
91
New
5
Increased
15
Reduced
36
Closed
16
Top Buys
| 1 |
Absci
ABSI
|
+$156M |
| 2 |
Invivyd
IVVD
|
+$121M |
| 3 |
LivaNova
LIVN
|
+$88.7M |
| 4 |
SLGC
SomaLogic, Inc. Class A Common Stock
SLGC
|
+$44.8M |
| 5 |
Stevanato
STVN
|
+$28M |
Top Sells
| 1 |
DexCom
DXCM
|
+$98.4M |
| 2 |
ZY
Zymergen Inc. Common Stock
ZY
|
+$60.9M |
| 3 |
SelectQuote
SLQT
|
+$46.5M |
| 4 |
Charles River Laboratories
CRL
|
+$40.1M |
| 5 |
Cigna
CI
|
+$37.9M |
Sector Composition
| 1 | Healthcare | 93.97% |
| 2 | Consumer Staples | 3.39% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Fate Therapeutics
FATE
$336M
| $768M | 13.39% |
12,957,222
| – | – |
|
|
ALLK
2
DELISTED
Allakos
ALLK
| $226M | 3.94% |
2,131,796
-85,200
| -4% | -$7.61M |
|
|
IGMS
3
DELISTED
IGM Biosciences
IGMS
| $225M | 3.93% |
3,425,455
| – | – |
|
4
argenx
ARGX
$54.1B
| $221M | 3.85% |
730,582
-59,700
| -8% | -$18.9M |
|
5
ADC Therapeutics
ADCT
$156M
| $204M | 3.57% |
7,529,329
+7,300
| +0.1% | +$187K |
|
|
FOLD
6
DELISTED
Amicus Therapeutics
FOLD
| $199M | 3.46% |
20,799,303
| – | – |
|
7
SkinHealth Systems
SKIN
$118M
| $194M | 3.39% |
7,483,706
+1,130,460
| +18% | +$24.9M |
|
|
8
LivaNova
LIVN
$4.41B
| $174M | 3.03% |
2,191,019
+1,079,335
| +97% | +$88.7M |
|
9
Beam Therapeutics
BEAM
$3.12B
| $172M | 3% |
1,975,006
-77,500
| -4% | -$7.79M |
|
10
Celldex Therapeutics
CLDX
$3B
| $164M | 2.87% |
3,043,298
+31,217
| +1% | +$1.46M |
|
11
Kymera Therapeutics
KYMR
$9.27B
| $164M | 2.86% |
2,793,708
+262,200
| +10% | +$15.2M |
|
|
NVTA
12
DELISTED
Invitae Corporation
NVTA
| $151M | 2.64% |
5,317,477
+670,084
| +14% | +$19.6M |
|
|
13
Invivyd
IVVD
$228M
| $137M | 2.39% |
+3,246,960
| New | +$121M |
|
|
DCPH
14
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
| $137M | 2.39% |
4,031,521
-213,200
| -5% | -$6.8M |
|
15
Replimune Group
REPL
$824M
| $121M | 2.11% |
4,078,112
-113,400
| -3% | -$3.68M |
|
16
Atara Biotherapeutics
ATRA
$76.6M
| $116M | 2.02% |
258,651
+668
| +0.3% | +$239K |
|
17
Shattuck Labs
STTK
$605M
| $115M | 2% |
5,619,914
| – | – |
|
18
Jazz Pharmaceuticals
JAZZ
$15.1B
| $112M | 1.96% |
861,401
+1,300
| +0.2% | +$196K |
|
19
Krystal Biotech
KRYS
$10.2B
| $104M | 1.81% |
1,982,432
-89,700
| -4% | -$5.31M |
|
|
SGEN
20
DELISTED
Seagen Inc. Common Stock
SGEN
| $99.7M | 1.74% |
587,374
-184,011
| -24% | -$28.6M |
|
|
21
Absci
ABSI
$1.66B
| $93.4M | 1.63% |
+8,031,094
| New | +$156M |
|
22
Nurix Therapeutics
NRIX
$2.45B
| $92.7M | 1.62% |
3,093,077
-97,000
| -3% | -$2.99M |
|
|
VERV
23
DELISTED
Verve Therapeutics
VERV
| $87.8M | 1.53% |
1,869,030
-67,500
| -3% | -$3.97M |
|
24
Scholar Rock
SRRK
$6.46B
| $84.2M | 1.47% |
2,550,205
+243,177
| +11% | +$8.51M |
|
25
Regenxbio
RGNX
$621M
| $84.2M | 1.47% |
2,008,001
-130,200
| -6% | -$4.68M |
|
Similar funds
ORI
GAI
HCMG
FMI
FCM
PP
AM
BFO